Europe Dalbavancin Market by Indication (Skin Infections, Soft Tissue Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Europe Dalbavancin Market Overview:

The Europe Dalbavancin Market is projected to be USD 75.9 Mn in 2022 to reach USD 150.2 Mn by 2032 at a CAGR of 7.2%.

Market.US announces the publication of its most recently generated research report titled, “Europe Dalbavancin Market by Indication (Skin Infections, Soft Tissue Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Country – Global Forecast to 2031”, which offers a holistic view of the Europe Dalbavancin market through systematic segmentation that covers every aspect of the target market.

Dalbavancin is a second-generation Lipoglycopeptide antibiotic developed to outperform natural Glycopeptides such as Vancomycin, Teicoplanin, etc., and is referred to as Xydalba in Europe.

It was the first drug approved as a Qualified Infectious Disease Product under the Generating Antibiotic Incentives Now (GAIN) Act, which is also a part of the FDA Safety and Innovation Act.

Furthermore, the modifications from the older glycoprotein family enabled Dalbavancin to have a similar mode of action, but with a higher activity rate and once-weekly dosing label.

It is an antibacterial drug used to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria. Commonly, Dalbavancin drug vials are available in 500mg of power in the form of powder and solution, which is administered orally or via the intravenous route.

Europe Dalbavancin Market Revenue (USD Mn), 2021–2031

Recent clinical studies conducted by the European Medicines Agency (EMA) have determined Dalbavancin as an advantageous drug over alternative drugs such as Vancomycin and Linezolid.

The effectiveness of this drug on skin diseases continues to result in increased rates of its adoption to treat various skin disorders, thereby further augmenting the revenue growth of this market.

The COVID-19 pandemic has put tremendous pressure on respective healthcare systems, due to a lack of adequate infrastructure and resource availability. Therefore, responding to such public healthcare emergencies and successfully minimizing their corresponding impacts, requires the effective utilization of every healthcare resource.

Failure to mitigate any damages to the healthcare industry could expose this system to severe discrepancies, particularly when these services are most needed, and may have long-term effects on the health and well-being of a given population.

In order to cope with this pandemic, the WHO, various governments, and the international community as a whole have also taken measures to address any stigmas concerning this virus. Several European economies are facing financial crises due to the onset of this pandemic.

Although public policy measures have been implemented to curb the spread of COVID-19, these measures have caused major operational disruptions for numerous companies, including those engaged in the healthcare industry.

The isolation of employees, supply chain disruptions, and sudden reductions in customer demand, have also led to more detrimental issues than initially expected.

For most individuals, the loss of income during this period has become a significant element that has suddenly led to unexpected financial pressure on both working capital and asset liquidity.

Europe Dalbavancin Market Attractiveness Analysis by Indication, 2015–2031

The Dalbavancin market in Europe is segmented on the basis of indication, distribution channel, and country. Based on the ‘indication’ segmentation of this market, the skin infections sub-segment is expected to account for a majority revenue share.

In terms of ‘distribution channel’ market segmentation, the hospital pharmacies sub-segment is expected to generate a majority revenue share over the forecast period.

On the basis of countries, the market in Germany is projected to account for the majority revenue share of the Dalbavancin market in Europe, with this sub-segment being anticipated to maintain its respective market position.

The research report on the Europe Dalbavancin market includes profiles of some of the major companies such as –

• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• and Advanz Pharma Corp. Ltd.
• among others.

Europe Dalbavancin Market Segmentation Based on Indication, Distribution Channel, and Country

Based on Indication:

• Skin Infections
• Soft Tissue Infections

Based on Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Country:

•  Germany
•  UK
•  France
•  Italy
•  Russia
•  Spain
•  Rest of Europe

For the Europe Dalbavancin Market research study, the following years have been considered to estimate the market size: